ATE520032T1 - Differentielle cytokinexpression bei einer menschlichen krebserkrankung - Google Patents

Differentielle cytokinexpression bei einer menschlichen krebserkrankung

Info

Publication number
ATE520032T1
ATE520032T1 AT07764767T AT07764767T ATE520032T1 AT E520032 T1 ATE520032 T1 AT E520032T1 AT 07764767 T AT07764767 T AT 07764767T AT 07764767 T AT07764767 T AT 07764767T AT E520032 T1 ATE520032 T1 AT E520032T1
Authority
AT
Austria
Prior art keywords
human cancer
cytokine expression
differential cytokine
differential
expression
Prior art date
Application number
AT07764767T
Other languages
German (de)
English (en)
Inventor
Giorgio Stassi
Christian Gieffers
Oliver Hill
Meinolf Thiemann
Matilde Todaro
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of ATE520032T1 publication Critical patent/ATE520032T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT07764767T 2006-06-21 2007-06-21 Differentielle cytokinexpression bei einer menschlichen krebserkrankung ATE520032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
ATE520032T1 true ATE520032T1 (de) 2011-08-15

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07764767T ATE520032T1 (de) 2006-06-21 2007-06-21 Differentielle cytokinexpression bei einer menschlichen krebserkrankung

Country Status (12)

Country Link
US (1) US20090324616A1 (https=)
EP (1) EP2041576B1 (https=)
JP (1) JP2010514409A (https=)
CN (1) CN101529253A (https=)
AT (1) ATE520032T1 (https=)
AU (1) AU2007263265A1 (https=)
BR (1) BRPI0713484A2 (https=)
CA (1) CA2656379A1 (https=)
DK (1) DK2041576T3 (https=)
ES (1) ES2371287T3 (https=)
RU (1) RU2009101783A (https=)
WO (1) WO2007147600A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
AU2015335607B2 (en) * 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
EP4053557A1 (en) * 2016-11-24 2022-09-07 Huvet Bio, Inc. Il-29 as a marker for a pancreatic disease
CN111051349A (zh) * 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1824886B1 (en) * 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy

Also Published As

Publication number Publication date
WO2007147600A2 (en) 2007-12-27
EP2041576A2 (en) 2009-04-01
BRPI0713484A2 (pt) 2012-11-06
EP2041576B1 (en) 2011-08-10
RU2009101783A (ru) 2010-07-27
DK2041576T3 (da) 2011-12-05
JP2010514409A (ja) 2010-05-06
CN101529253A (zh) 2009-09-09
US20090324616A1 (en) 2009-12-31
CA2656379A1 (en) 2007-12-27
AU2007263265A1 (en) 2007-12-27
ES2371287T3 (es) 2011-12-29
WO2007147600A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
GB2566371A (en) Methods and systems for collecting spirometry data
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
GB2478065A (en) Method and systems for personalized action plans
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2009026657A8 (en) Flavonoid ppar agonists
BRPI0811581A2 (pt) Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
ATE554396T1 (de) Diagnose- und therapiewerkzeuge für krankheiten, die die gefässfunktion verändern
DE602005003570D1 (de) Rohr- und universalkupplung für die zufuhr von zahnmedizinischen oder chirurgischen instrumenteen
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
MX2007006355A (es) Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico.
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
Armitage AAP centennial commentary: theme 3: Evolution and application of classification systems for periodontal diseases--a retrospective commentary
WO2008106076A3 (en) Methods for monitoring disease progression of alzheimer's disease using csf markers from longitudinal samples
EP2148934A4 (en) MATRIX MARKER MODEL AND METHOD FOR THE TEST AND TREATMENT OF ARTHRITIS AND RELATED DISEASES
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
MX2009011388A (es) Inhibidores de polimerasa y su uso para el tratamiento de tumores.
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
AU2018263871A1 (en) Tumor vs. matched normal cfRNA
WO2015092444A3 (en) Biomarkers
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties